Non-vitamin-K oral anticoagulants (NOACs) for the prevention of secondary stroke

  title={Non-vitamin-K oral anticoagulants (NOACs) for the prevention of secondary stroke},
  author={H. Diener and G. Ntaios and M. O'Donnell and J. Easton},
  journal={Expert Opinion on Pharmacotherapy},
  pages={1597 - 1602}
  • H. Diener, G. Ntaios, +1 author J. Easton
  • Published 2018
  • Medicine
  • Expert Opinion on Pharmacotherapy
  • ABSTRACT Introduction: In patients with atrial fibrillation (AF), oral anticoagulation with vitamin K antagonists (VKA) (warfarin, phenprocoumon) is effective both for primary and secondary stroke prevention with a 60–70% relative reduction in stroke risk compared with placebo. Mortality is reduced by 26%. VKA have a number of well-documented shortcomings which were overcome by non-vitamin-K oral anticoagulants (NOACs). Areas covered: Results of randomized trials for four NOACs (apixaban… CONTINUE READING
    8 Citations
    Non-vitamin K oral anticoagulants for secondary stroke prevention in patients with atrial fibrillation
    • 1
    Anticoagulant Selection in Relation to SAMe-TT2R2 Score in Patients with Atrial Fibrillation: The GLORIA-AF Registry.
    Stroke: Insights into Thromboembolism Treatment and Prevention through the Decades.
    • 1
    • PDF
    Beginn der Antikoagulation nach akutem Schlaganfall


    Novel oral anticoagulants in secondary prevention of stroke.
    • 11
    Apixaban versus warfarin in patients with atrial fibrillation.
    • 4,528
    • PDF
    Choosing a particular oral anticoagulant and dose for stroke prevention in individual patients with non-valvular atrial fibrillation: part 2.
    • 76
    • PDF
    Apixaban in patients with atrial fibrillation.
    • 1,532
    • PDF
    Dabigatran versus warfarin in patients with atrial fibrillation.
    • 6,405
    • PDF